34. Bagchi MK, Tsai SY, Tsai MJ, O’Malley BW (1990) Identification of a functional intermediate in receptor activation in progesterone-dependent cell- free transcription. Nature 345: 547–550. 35. Laue L, Chrousos GP, Loriaux DL, Barnes K, Munson P, et al. (1988) The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocor- ticotropin response to ovine corticotropin releasing hormone in man. J Clin Endocrinol Metab 66: 290–293. 36. Sartor O, Cutler GJ (1996) Mifepristone: treatment of Cushing’s syndrome. Clin Obstet Gynecol 39: 506–510. 37. Johanssen S, Allolio B (2007) Mifepristone (RU 486) in Cushing’s syndrome. European Journal of Endocrinology 157: 561–569. 38. Yokoyama WM, Kim S, French AR (2004) The dynamic life of natural killer cells. Annu Rev Immunol 22: 405–429. 39. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, et al. (2007) Acquisition of murine NK cell cytotoxicity requires the translation of a pre- existing pool of granzyme B and perforin mRNAs. Immunity 26: 798–811. 40. Grossman WJ, Revell PA, Lu ZH, Johnson H, Bredemeyer AJ, et al. (2003) The orphan granzymes of humans and mice. Curr Opin Immunol 15: 544–552. 41. Lieberman J (2003) The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3: 361–370. 42. Trapani JA, Smyth MJ (2002) Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2: 735–747. 43. Davis DM (2002) Assembly of the immunological synapse for T cells and NK cells. Trends Immunol 23: 356–363. 44. Darmon AJ, Nicholson DW, Bleackley RC (1995) Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377: 446–448. 45. Colucci F, Caligiuri MA, Di Santo JP (2003) What does it take to make a natural killer? Nat Rev Immunol 3: 413–425. 46. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, et al. (2000) Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 1: 419–425. Mifepristone Augments uNK Cell-Cytotoxicity 47. Chiossone L, Vitale C, Cottalasso F, Moretti S, Azzarone B, et al. (2007) Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood 109: 3767–3775. 48. Clark AR, Lasa M (2003) Crosstalk between glucocorticoids and mitogen- activated protein kinase signalling pathways. Curr Opin Pharmacol 3: 404–411. 49. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, et al. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19: 197–223. 50. Vivier E, Nunes JA, Vely F (2004) Natural killer cell signaling pathways. Science 306: 1517–1519. 51. Li C, Ge B, Nicotra M, Stern JN, Kopcow HD, et al. (2008) JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci U S A 105: 3017–3022. 52. Wei S, Gamero AM, Liu JH, Daulton AA, Valkov NI, et al. (1998) Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J Exp Med 187: 1753–1765. 53. Lu CC, Chen JK (2010) Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J Cell Physiol 223: 343–351. 54. Gonzalez R, Ruiz-Leon Y, Gomendio M, Roldan ER (2010) The effect of glucocorticoids on ERK-1/2 phosphorylation during maturation of lamb oocytes and their subsequent fertilization and cleavage ability in vitro. Reprod Toxicol 29: 198–205. 55. Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, et al. (2002) Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem 277: 47444–47450. 56. Rambal AA, Panaguiton ZL, Kramer L, Grant S, Harada H (2009) MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia 23: 1744–1754. PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36413